Focus: Axiom is a public biotechnology company specializing in AI-driven toxicity modeling, with a diversified pipeline spanning neurology, ophthalmology, infectious diseases, and gastroenterology. The company operates at a pre-revenue or early-revenue stage with limited disclosed financials.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
10 added, 9 removed. Backfill posture.
High-risk, early-stage AI biotech with compelling technology but critical cash constraints and execution uncertainty; suitable only for risk-tolerant candidates with equity optionality.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Axiom
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Axiom's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Blast Vein Revealed: Boomer Shooter Roguelite Uses Drug Trip as Design Engine - Tech Times
Blast Vein Revealed: Boomer Shooter Roguelite Uses Drug Trip as Design Engine Tech Times
SpaceX listing lifts Boryung’s space bets as Korea drugmaker expands oncology, CDMO - CHOSUNBIZ - Chosunbiz
SpaceX listing lifts Boryung’s space bets as Korea drugmaker expands oncology, CDMO - CHOSUNBIZ Chosunbiz
8-K Filing: GRAHAM CORP (GHM) (CIK 0000716314) — EX-99.1
EX-99.1
Boryung positions for post-ISS era with bet on commercial space stations - koreabiomed.com
Boryung positions for post-ISS era with bet on commercial space stations koreabiomed.com
Korea's $60 million bet on space medicine faces years before a payoff - koreabiomed.com
Korea's $60 million bet on space medicine faces years before a payoff koreabiomed.com
8-K Filing: Inflection Point Acquisition Corp. VI (IPFX, IPFXU, IPFXW) (CIK 0002102041) — INVESTOR PRESENTATION, DATED JUNE 2026
INVESTOR PRESENTATION, DATED JUNE 2026
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Nontargeted LC-HRMS-Based Strategies as a Tool to Study the Behavior of Chemical Attribution Signatures of Organophosphorus in Complex Environmental Matrices.
In-space manufacturing of optical lenses: Fluidic Shaping aboard the International Space Station.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo